New targeted therapies for NSCLC that have been recently approved or are under review include amivantimab for EGFR exon 20 insertion mutations, sotorasib for KRAS G12C, selpercatinib and praseltinib for RET fusions, capmatinib and tepotinib for MET alterations, and trastuzumab deruxtecan for HER2 insertion mutations [15,16,17,18,19,20,21]. Here, EGFR is linked to non-small cell lung carcinoma.